Sanara MedTech (NASDAQ:SMTI – Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Monday, August 14th. Persons that are interested in participating in the company’s earnings conference call can do so using this link.
Sanara MedTech (NASDAQ:SMTI – Get Free Report) last issued its earnings results on Monday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter. The firm had revenue of $15.52 million during the quarter. Sanara MedTech had a negative return on equity of 25.60% and a negative net margin of 18.67%. On average, analysts expect Sanara MedTech to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Sanara MedTech Stock Performance
Shares of NASDAQ SMTI opened at $45.99 on Friday. The firm’s 50 day moving average price is $40.92 and its 200-day moving average price is $41.32. Sanara MedTech has a 52-week low of $25.78 and a 52-week high of $50.18. The company has a market cap of $385.40 million, a PE ratio of -36.79 and a beta of 1.79.
Analyst Upgrades and Downgrades
View Our Latest Research Report on SMTI
Institutional Investors Weigh In On Sanara MedTech
Several hedge funds and other institutional investors have recently made changes to their positions in SMTI. BlackRock Inc. raised its stake in shares of Sanara MedTech by 1,900.7% in the second quarter. BlackRock Inc. now owns 172,424 shares of the company’s stock valued at $6,914,000 after acquiring an additional 163,806 shares during the period. Geode Capital Management LLC grew its position in Sanara MedTech by 133.2% during the 2nd quarter. Geode Capital Management LLC now owns 68,486 shares of the company’s stock worth $2,746,000 after purchasing an additional 39,124 shares during the last quarter. Northern Trust Corp grew its position in Sanara MedTech by 470.3% during the 2nd quarter. Northern Trust Corp now owns 31,177 shares of the company’s stock worth $1,250,000 after purchasing an additional 25,710 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Sanara MedTech in the 1st quarter valued at $726,000. Finally, Susquehanna International Group LLP purchased a new stake in shares of Sanara MedTech in the 4th quarter valued at $693,000. Hedge funds and other institutional investors own 5.07% of the company’s stock.
About Sanara MedTech
Sanara MedTech Inc develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It also offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution.
Featured Stories
- Five stocks we like better than Sanara MedTech
- How and Why to Invest in Oil Stocks
- Investing in Coffee: 3 Great Strategies to Consider
- Earnings Per Share Calculator: How to Calculate EPS
- 5 Best Stocks to Buy in a Bear Market
- How to Invest in Energy
- 3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.
